IP Library Granted Patent US 10,744,097
Granted Patent B2
US 10,744,097 · App. 15/257,274 · Granted Aug 18, 2020

Abuse resistant capsule

Inventor: Simone Wengner (Eberbach, DE)
Assignee: R.P. Scherer Technologies, LLC
A61K9/4866A61K9/06A61K9/08A61K9/10A61K9/4825A61K9/4858A61K9/4875A61K9/4891A61K31/137A61K31/196A61K31/485A61K47/14A61K47/26A61K47/36A61K47/44A61K9/485
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,744,097
App. No.
15/257,274
Granted
Aug 18, 2020
Kind
B2
Abstract

The present invention is directed to an immediate release and extended release capsule or capsule fill which mitigates the abuse of abuse-susceptible active pharmaceutical ingredients by direct intravenous injection. The fill comprises a parenteral abuse resistant liquid formulation which when mixed with water and heated, results in a turbid, viscous or bubbling mixture that is not injectable with a standard insulin syringe. The abuse-susceptible active pharmaceutical ingredient is selected from the group consisting of opiates, opioids, tranquillizers, stimulants and narcotics.

Claims (17)

1. An immediate release parenteral abuse resistant capsule comprising a parenteral abuse resistant liquid and a shell, the parenteral abuse resistant liquid comprising:

(a) an abuse-susceptible active pharmaceutical ingredient which is at least one stimulant;

(b) 2 to 5 wt. % xanthan gum;

(c) polysorbate 80 and optionally sorbitan monolaurate;

(d) 10 to 70 wt. % medium chain triglycerides; and

(e) 1 to 5 wt. % colloidal anhydrous silica; wherein the wt. % values are based on the total weight of the parenteral abuse resistant liquid;

such that a mixture of about 250 to about 1000 milligrams of the abuse resistant liquid with 5 milliliters of water at the mixture's boiling point forms a viscous phase, wherein about 33% or less of the pharmaceutically active ingredient can be recovered from the viscous phase drawn up into a 25 millimeter needle having an inner diameter of 0.60 millimeters,

wherein the capsule releases more than 80% of the active pharmaceutical ingredient within the gastrointestinal tract within 30 minutes of administration.

2. The parenteral abuse resistant capsule of claim 1 , wherein the viscous phase cannot pass through a 25 millimeter needle having an inner diameter of 0.60 millimeters.

3. The parenteral abuse resistant capsule of claim 1 , wherein the stimulant is an amphetamine, a prodrug thereof, a pharmaceutically acceptable salt thereof, and a solvate thereof.

4. The parenteral abuse resistant capsule of claim 1 , that is resistant to alcohol dose dumping.

5. The parenteral abuse resistant capsule of claim 1 , that is resistant to solvent, acidic or aqueous extraction.

6. The parenteral abuse resistant capsule of claim 1 , wherein the capsule is a soft capsule.

7. The parenteral abuse resistant capsule of claim 1 , wherein the capsule is a hard gelatin capsule.

8. The parenteral abuse resistant capsule of claim 1 , wherein the parenteral abuse resistant liquid comprises 4 to 52.7 wt. % polysorbate 80, based on the total weight of the parenteral abuse resistant liquid.

9. The parenteral abuse resistant capsule of claim 8 , wherein the parenteral abuse resistant liquid further comprises sorbitan monolaurate.

10. The parenteral abuse resistant capsule of claim 1 , further comprising 40 to 70 wt. % hard fat based on the total weight of the parenteral abuse resistant liquid.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2026
From: WENGNER, SIMONE
To: R.P. SCHERER TECHNOLOGIES, LLC
Reel/Frame 075686/0226 →
SECURITY INTEREST Recorded Dec 19, 2024
From: CATALENT CTS (KANSAS CITY), LLC; REDWOOD BIOSCIENCE, INC.; R.P. SCHERER TECHNOLOGIES, LLC; CATALENT WELLNESS, LLC; CATALENT PHARMA SOLUTIONS, INC.; CATALENT WELLNESS NEW JERSEY, LLC; CATALENT MARYLAND, INC.; CATALENT GREENVILLE, INC.; CATALENT MICRON TECHNOLOGIES, INC.; CATALENT SAN DIEGO, INC.; CATALENT WELLNESS VIRGINIA, LLC; CATALENT USA PACKAGING, LLC; CATALENT PHARMA SOLUTIONS, LLC
To: ARES CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 069743/0458 →
Continuity (3)
Division 14204259 · Mar 11, 2014
Provisional Application 61794714 · Mar 15, 2013
Related Publication 20160374948A1 · Dec 29, 2016